Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

Phase III trial meets primary endpoint for Allergan’s fibroid treatment

May 9, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, fibroid, phase 3, phase III, ulipristal, ulipristal acetate, uterine fibroid

Allergan (NYSE: AGN), in collaboration with Gedeon Richter, has announced positive results from a pivotal Phase III trial evaluating the …
News

Weekly Movers: Bind Therapeutics, Sarepta, Idexx…

May 9, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Pfizer (NYSE: PFE) and Amgen (Nasdaq: AMGN) are rumoured to be considering a bid for Medivation just as French drug …
Feature

Clovis cuts staff by 35% after FDA knock back on lung cancer drug

May 6, 2016 Manufacturing and Production, Research and Development, Sales and Marketing FDA, Q1 results, clovis, failure, job cuts, job losses, rociletinib, workforce

Clovis Oncology (NASDAQ: CLVS) is set to cut up to 35% of its workforce following the US Food and Drug …
News

NICE recommends Sanofi, Amgen cholesterol drugs

May 6, 2016 Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
News

KemPharm’s pain drug fails to get FDA committee backing for abuse-deterrent capabilities; shares plunge

May 6, 2016 Medical Communications, Sales and Marketing

Shares in KemPharm (Nasdaq: KMPH) more than halved in pre-market trading after a US Food and Drug Administration advisory panel …
News

Focus: Medivation tug-of-war rumbles on

May 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war

Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …
Feature

Merck & Co Q1 sales hurt by generics, currency impact

May 6, 2016 Medical Communications, Sales and Marketing Financial, Merck & Co, Q1, Revenye, earnings, results, sales

US pharma major Merck & Co (NYSE: MRK) posted a drop in first-quarter sales impacted the launch of generic competition …
News

Valeant announces new patient access and pricing committee; vows to correct past “mistakes”

May 6, 2016 Medical Communications, Sales and Marketing Valeant, joseph papa, new committee, patient access, price gouging, pricing

Valeant (NYSE: VRX) has announced the establishment of a new patient access and pricing committee that will be responsible for …
News

Pfizer teams up with Wave Life Sciences for metabolic disease research

May 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, metabolic disease, nucelic acid therapies, partnership, wave life sciences

Pfizer (NYSE: PFE) has entered into a research, license and option agreement with Wave Life Sciences (NASDAQ: WVE) for the …
News

Amgen looking to join the fray, mulling Medivation bid – Reports

May 5, 2016 Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …
News

Sanofi sends letter to Medivation board; claims shareholders want takeover

May 5, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Medivation, Sanofi, board, brandicourt, hostile, shareholders, takeover

The CEO of Sanofi has issued a strongly worded letter to the board at Medivation, indicating that shareholders support their …
News

Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe

May 5, 2016 Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma

The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …
News

One in three antibiotic prescriptions in US unnecessary, says CDC

May 5, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDC, antibiotic, prescribing, prescriptions, unnecessary

Approximately 30% of all prescriptions of antibiotics in the United States are unnecessary, according to new data published by the …
News

Bayer’s liver cancer drug meets primary endpoint in late stage trial

May 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial

Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …
News

Biogen to spin off its haemophilia business

May 4, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off

Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …
News
The Gateway to Local Adoption Series

Latest content

Scots neonatal innovations target hearing loss and earlier care

August 28, 2026

FDA grants De Novo authorisation to light-filtering device for migraine

August 28, 2026

Southgate opens Innovation Lab for logistics and fulfilment development

August 27, 2026

Bioptimus partners with Cancer Research Horizons to expand AI cancer data set

August 27, 2026

Agentis Health Group acquires Clinical Pharmacist Solutions

August 26, 2026